Inspire Medical Systems, Inc. (INSP)
INSP Stock Plunges Despite Q2 Earnings Beat, Gross Margin Contracts
Inspire Medical tops second-quarter 2025 earnings estimates and posts solid revenue growth, but trims 2025 guidance amid margin pressure.
Inspire Medical Systems, Inc. (INSP) Q2 2025 Earnings Call Transcript
Inspire Medical Systems, Inc. (NYSE:INSP ) Q2 2025 Earnings Conference Call August 4, 2025 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Richard J. Buchholz - Chief Financial Officer Timothy P.
Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics
The headline numbers for Inspire (INSP) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Inspire Medical Systems (INSP) Q2 Earnings and Revenues Surpass Estimates
Inspire Medical Systems (INSP) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.32 per share a year ago.
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy?
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Is the Options Market Predicting a Spike in Inspire Medical Systems Stock?
Investors need to pay close attention to INSP stock based on the movements in the options market lately.
Inspire Medical Systems: Investors Should Sleep Better From Here Onwards
Inspire Medical's growth remains strong, with 2025 seen as a transition year due to the Inspire V launch, causing near-term margin volatility. Valuations look more attractive: shares trade at just 4x sales, a significant discount from previous highs, while the business is profitable and growing. Concerns about GLP-1 drugs impacting demand are likely overblown, as these patients were not ideal candidates for Inspire's therapy anyway.
All You Need to Know About Inspire (INSP) Rating Upgrade to Buy
Inspire (INSP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 39.04% Upside in Inspire (INSP): Here's What You Should Know
The consensus price target hints at a 39% upside potential for Inspire (INSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
INSP Stock Gains Following Q1 Earnings Beat, Gross Margin Contracts
Inspire Medical's first-quarter 2025 performance reflects increased market penetration in existing centers and expansion into new territories and centers, along with strong domestic results.
Inspire Medical Systems (INSP) Surpasses Q1 Earnings and Revenue Estimates
Inspire Medical Systems (INSP) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.23 per share. This compares to loss of $0.34 per share a year ago.
